Mineralys Therapeutics announced on February 4, 2025, that it has completed enrollment in its Phase 2 Explore-CKD trial. This trial is evaluating the efficacy and safety of lorundrostat for the treatment of hypertension in subjects with Stage 2 to 3b Chronic Kidney Disease (CKD) and albuminuria.
The completion of enrollment is a key operational milestone, indicating the trial is progressing as planned. The company continues to anticipate announcing topline data from the Explore-CKD trial in the second quarter of 2025.
This trial aims to expand lorundrostat's potential application into cardiorenal metabolic conditions beyond hypertension, addressing a significant unmet medical need in patients with compromised renal function.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.